Previous close | 5,904.50 |
Open | 5,909.90 |
Bid | 5,916.85 x 0 |
Ask | 5,919.55 x 0 |
Day's range | 5,880.90 - 5,945.00 |
52-week range | 4,525.00 - 6,874.45 |
Volume | |
Avg. volume | 527,003 |
Market cap | 850.761B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 108.93 |
EPS (TTM) | 54.32 |
Earnings date | 30 May 2024 |
Forward dividend & yield | 15.00 (0.25%) |
Ex-dividend date | 20 Feb 2024 |
1y target est | 4,426.63 |
The Indian market has shown robust growth, with a 1.7% increase in the past week and an impressive 45% rise over the last year, alongside forecasts predicting annual earnings growth of 16%. In such a thriving environment, stocks with high insider ownership can be particularly appealing as they often signal strong confidence from those who know the company best.
The Indian market has shown robust performance, gaining 1.8% recently and an impressive 46% over the past 12 months, with earnings expected to grow by 18% annually. In this thriving environment, stocks with high insider ownership and strong earnings growth can be particularly compelling, as they often signal confidence from those who know the company best.
Aster DM Healthcare posted its first increase in quarterly profit since the first quarter of fiscal 2023 on the back of strong performance at the company's domestic hospitals segment. Consolidated net profit for the third quarter rose 28.6% to 1.79 billion rupees ($21.6 million), the company said on Thursday. While Aster's India business accounts for roughly a quarter of its revenue and Gulf Cooperation Council countries the rest, the company has focussed on expanding within India.